Unintended consequences - The cost of preventing preterm births after FDA approval of a branded version of 17OHP

New England Journal of Medicine

Volumn 364, Issue 18, 2011, Pages 1689-1691

  Armstrong, Joanne ^a  

^a AETNA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTONORONE CAPROATE; 17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; HYDROXYPROGESTERONE CAPROATE; PROGESTERONE DERIVATIVE;

COST CONTROL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MEDICAID; MEDICAL CARE; PATIENT ADVOCACY; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; ARTICLE; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; ECONOMICS; FEMALE; PATENT; PREGNANCY; PREMATURITY; UNITED STATES;

DRUG APPROVAL; DRUG COMPOUNDING; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; HYDROXYPROGESTERONES; OBSTETRIC LABOR, PREMATURE; PATENTS AS TOPIC; PREGNANCY; PREMATURE BIRTH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955729289     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1102796     Document Type: Review

References (5)

1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85. (Pubitemid 36682816)
2. Behrman RE, Butler AS, eds. Preterm birth: causes, consequences, and prevention. Washington, DC: National Academy Press, 2006.
3. Makena wholesale acquisition cost and average wholesale price. South San Francisco, CA: First Databank, Inc., March 4, 2011.
4. Food and Drug Administration compliance policy guide. Section 460.200 pharmacy compounding. May 29, 2002. (http://www.fda.gov/ICECI/ComplianceManuals/ CompliancePolicyGuidanceManual/ucm116791.htm.)
5. Petrini JR, Callaghan WM, Klebanoff M, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267-72. (Pubitemid 40229440)